Welcome to our dedicated page for Elanco Animal Health SEC filings (Ticker: ELAN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Elanco Animal Health's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Elanco Animal Health's regulatory disclosures and financial reporting.
Elanco Animal Health Inc director Michael J. Harrington purchased 5,000 shares of common stock on 2026-08-12 in an open market or private transaction at a price of $21.82 per share. Following this transaction, his directly held position increased to 131,451 shares of Elanco common stock.
Simmons Jeffrey N reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health Inc reported that President, CEO and Director Jeffrey N. Simmons received a grant of 127.7997 Deferred Stock Units on 2026-08-07 at a reference value of $22.12 per unit. Each deferred stock unit represents the right to receive one share of common stock or the cash equivalent and will settle in cash or shares following termination of employment or in a specified future year under the Executive Deferral and Stock Match Plan. Following this award, Simmons holds 25,012.1875 Deferred Stock Units directly.
Elanco Animal Health EVP and CFO Robert M. VanHimbergen reported two transactions on August 7, 2026. He received a grant of 8.9069 Deferred Stock Units, each representing the right to one share of common stock or cash, bringing his Deferred Stock Unit balance to 133.6048. On the same date, he purchased 4,200 shares of common stock in multiple transactions at a weighted average price of $23.0776 per share, with individual prices ranging from $23.01 to $23.09. Following these purchases, he directly owns 137,516 shares of Elanco Animal Health common stock.
Modi Rajeev A. reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health Inc reported that Executive Vice President U.S. Pet Health and Global Digital Transformation Rajeev A. Modi received a grant of 66.7690 Deferred Stock Units tied to Company common stock at a reference price of $22.1200 per unit. Each unit represents the right to receive one share of common stock or the cash equivalent, settling in cash or shares after termination of employment or in a specified future year under the Executive Deferral and Stock Match Plan. Following this award, Modi holds a total of 9708.6964 Deferred Stock Units directly.
Elanco Animal Health Inc director Paul Herendeen reported an open-market purchase of 10,000 shares of Common Stock on August 7, 2026 at $23.685 per share. Following this transaction, his reported direct ownership increased to 111,687 common shares of Elanco Animal Health Inc.
Elanco Animal Health reported stronger results for the quarter ended June 30, 2026. Revenue rose to $1,368 million from $1,241 million, led by Pet Health ($718 million) and Farm Animal ($633 million). Gross margin improved to 58.3%, and net income increased to $54 million, or diluted EPS of $0.11, up from $0.02.
For the first half of 2026, revenue grew 13% to $2,739 million and net income reached $111 million (EPS $0.22). Operating cash flow was $290 million. Elanco closed the $243 million acquisition of AHV International to expand its cattle portfolio and is executing a 2025 restructuring plan expected to deliver $25 million savings in 2026 and $60 million in 2027.
Elanco ended the period with $530 million in cash, total debt (excluding finance leases) of $3,663 million, and a $315 million liability for sale of future XDEMVY royalties carrying an effective interest rate of 18.3%. The company reports ample liquidity with an undrawn $750 million revolver and interest-rate and currency hedges covering much of its debt and non‑U.S. operations.
Elanco Animal Health Incorporated reported strong second quarter 2026 results. Revenue was $1,368 million, up 10% year-over-year, with 8% organic constant currency growth. Pet Health revenue rose to $718 million and Farm Animal revenue to $633 million. Gross margin expanded to 58.3%, or 58.1% on an adjusted basis, up 80 basis points and ahead of the company’s expectations. Reported net income was $54 million and adjusted net income $174 million; adjusted EPS increased to $0.34 from $0.26, and adjusted EBITDA grew to $288 million, for a 21.2% margin.
Cash from operations increased to $277 million. As of June 30, 2026, the net leverage ratio was 3.1x trailing twelve month adjusted EBITDA, a 0.5x improvement versus December 31, 2025. Growth was led by U.S. Pet Health and U.S. Farm Animal, each up 11% organically, with blockbuster dermatology product Zenrelia and Credelio Quattro cited as key contributors.
The company raised full-year 2026 guidance, including revenue of $5.09–$5.14 billion, adjusted EBITDA of $1.01–$1.035 billion, adjusted EPS of $1.10–$1.16, and an innovation revenue target of $1.25 billion. It now expects 6–7% organic constant currency revenue growth and an improved year-end net leverage ratio target of approximately 3.0x. Third quarter 2026 guidance includes revenue of $1.195–$1.22 billion, adjusted EBITDA of $200–$215 million and adjusted EPS of $0.19–$0.22.
Simmons Jeffrey N reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health Inc reported that President, CEO and Director Jeffrey N. Simmons received a grant of 113.4857 deferred stock units on 2026-07-24 at $24.9100 per unit, increasing his direct deferred stock unit holdings to 24,884.3878 units. Each unit represents the right to receive one share of common stock or the cash equivalent and will settle in cash or shares after termination of employment or in a specified future year under the company’s Executive Deferral and Stock Match Plan.
Modi Rajeev A. reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health Inc reported that Executive Vice President U.S. Pet Health and Global Digital Transformation Rajeev A. Modi received a grant of 59.2906 deferred stock units on 2026-07-24 at a reference value of $24.91 per unit. Each unit represents the right to receive one share of common stock or the cash equivalent and will settle in cash or shares after termination of employment or in a specified future year under the Executive Deferral and Stock Match Plan. Following this grant, Modi holds 9,641.9274 deferred stock units directly.
VanHimbergen Robert M reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health Inc reported that EVP and CFO Robert M. VanHimbergen received a grant of 7.9093 deferred stock units on July 24, 2026 at $24.91 per unit. Each deferred stock unit represents the right to receive one share of common stock or the cash equivalent and will settle in cash or shares following termination of employment or in a specified future year under the Executive Deferral and Stock Match Plan. After this compensation-related grant, he holds 124.6979 deferred stock units directly.